MARKET

EPZM

EPZM

Epizyme
NASDAQ

Real-time Quotes | Nasdaq Last Sale

15.51
-1.02
-6.17%
After Hours: 15.51 0 0.00% 17:30 03/31 EDT
OPEN
16.50
PREV CLOSE
16.53
HIGH
16.50
LOW
14.89
VOLUME
1.28M
TURNOVER
--
52 WEEK HIGH
27.82
52 WEEK LOW
9.74
MARKET CAP
1.56B
P/E (TTM)
-8.1026
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of EPZM and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 9 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average EPZM stock price target is 29.33 with a high estimate of 36.00 and a low estimate of 17.00.

EPS

EPZM News

More
  • Epizyme (EPZM) Down 24.9% Since Last Earnings Report: Can It Rebound?
  • Zacks · 6d ago
  • Looking At The Investment Case For Epizyme
  • Seeking Alpha - Article · 03/20 18:21
  • Epizyme Appoints Jeffery Kutok, M.D., Ph.D., as Chief Scientific Officer
  • Business Wire · 03/20 11:30
  • 3 Cancer Treatment Stocks to Buy Right Now
  • MotleyFool.com · 03/19 10:45

Industry

Biotechnology & Medical Research
-0.26%
Pharmaceuticals & Medical Research
-0.17%

Hot Stocks

Symbol
Price
%Change

About EPZM

Epizyme, Inc. is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company is engaged in the discovery and development of novel epigenetic therapies for cancer patients. The Company develops small molecule inhibitors of a class of enzymes known as histone methyltransferases (HMTs). The Company develops small molecule inhibitors of other chromatin modifying proteins (CMPs). The Company's lead product candidate, tazemetostat, is a potent and selective inhibitor of the enhancer of zeste homolog 2 (EZH2) histone methyltransferases (HMT), an enzyme that plays an important role in various cancers. The Company is evaluating tazemetostat in a Phase II study in adults with relapsed or refractory non-Hodgkin lymphoma (NHL), and one Phase I study in children with molecularly defined solid tumors. The Company owns the global development and commercialization rights to tazemetostat outside of Japan.
More

Webull offers kinds of Epizyme Inc stock information, including NASDAQ:EPZM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EPZM stock news, and many more online research tools to help you make informed decisions.